Page last updated: 2024-12-06

tris(2,2'-bipyridine)ruthenium(II)

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tris(2,2'-bipyridine)ruthenium(II), commonly abbreviated as [Ru(bpy)3]2+, is a luminescent coordination compound that has been extensively studied for its photophysical properties and potential applications in various fields. Its synthesis involves reacting ruthenium chloride with 2,2'-bipyridine in a suitable solvent. [Ru(bpy)3]2+ exhibits strong luminescence in the visible region, owing to the presence of a metal-to-ligand charge transfer (MLCT) transition. This luminescence has found applications in areas such as luminescent probes, solar energy conversion, and bioimaging. The compound's photostability and long excited-state lifetime make it a promising candidate for these applications. [Ru(bpy)3]2+ has also been explored as a photosensitizer in photodynamic therapy for cancer treatment, where it can generate reactive oxygen species upon light irradiation, leading to cell death. The study of [Ru(bpy)3]2+ continues to be driven by its unique photophysical properties and its potential to contribute to advancements in diverse scientific and technological domains.'

tris(2,2'-bipyridyl)ruthenium(II): a fluorescent dye; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65240

Synonyms (9)

Synonym
tris(2,2'-bipyridine)ruthenium ii
tris(bipyridine)ruthenium(ii)
ruthenium(2+), tris(2,2'-bipyridine-n,n')-, (oc-6-11)-
ruthenium ii tris(2,2'-bipyridine)
tris(2,2'-bipyridyl)ruthenium(ii)
ru(ii)-tris(bipyridyl)
tris(2,2/'-bipyridine)ruthenium ii
2-pyridin-2-ylpyridine;ruthenium(2+)
Q27123697

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Compared to the unmodified monomer, the photoinduced covalent oligomeric species demonstrated increased toxic effects on differentiated neuronal-like SH-SY5Y cells."( Biophysical properties and cellular toxicity of covalent crosslinked oligomers of α-synuclein formed by photoinduced side-chain tyrosyl radicals.
Borsarelli, CD; Falomir-Lockhart, LJ; Fauerbach, JA; Hsiao, HH; Jares-Erijman, EA; Jovin, TM; Ostatná, V; Paleček, E; Urlaub, H, 2012
)
0.38

Compound-Compound Interactions

ExcerptReferenceRelevance
" In base to the differences in the kinetic behaviour of ofloxacin with respect to ciprofloxacin and norfloxacin, binary mixtures of the drugs were resolved by using the time-resolved chemiluminescence signals, in combination with first-order partial least-squares (PLS) multivariate calibration."( Resolution of ofloxacin-ciprofloxacin and ofloxacin-norfloxacin binary mixtures by flow-injection chemiluminescence in combination with partial least squares multivariate calibration.
Alañón Molina, A; Durán Merás, I; Jiménez Girón, A; Muñoz de la Peña, A; Murillo, JA, 2007
)
0.34

Dosage Studied

ExcerptRelevanceReference
" The method was applied to determination of 1 to 5% of I in semisolid dosage forms (gels and ointments)."( Sequential injection analysis (SIA)-chemiluminescence determination of indomethacin using tris[(2,2'-bipyridyl)]ruthenium(III) as reagent and its application to semisolid pharmaceutical dosage forms.
Calatayud, JM; Mervartová, K; Polásek, M, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
fluorochromeA fluorescent dye used to stain biological specimens.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
ruthenium coordination entity
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (210)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's68 (32.38)29.6817
2010's125 (59.52)24.3611
2020's17 (8.10)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.63 (24.57)
Research Supply Index5.41 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index41.19 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews8 (3.60%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other214 (96.40%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]